The College of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
J Drug Target. 2011 Apr;19(3):161-70. doi: 10.3109/10611861003801842. Epub 2010 May 13.
Polyethylene glycol-modified GoldMag nanoparticles (PGMNs) were synthesized and characterized by several analysis including transmission electron microscopy, dynamic light scattering, Fourier transform infrared spectroscopy, and vibrating sample magnetometer. Here, we showed that the composite nanoparticles have a saturated magnetization of 34 emu/g with an average diameter of 50 nm. The kinetics analysis showed the maximum doxorubicin (DOX) loading capacity of PGMNs is 107.78 mg/g. The PGMNs loaded with DOX (DOX-loaded PGMNs) exhibited a controlled drug release pattern within the first 4 h and then a slowly, sustained release pattern for 4 days. The biodistribution of DOX-loaded PGMNs in vivo indicated that the concentrations of DOX in liver exposed to magnetic field group (60.7 ± 8.14, 53.6 ± 4.89, 44.8 ± 6.41, and 38.4 ± 2.58 ng/g) were significantly higher than those of no applied magnetic field group (40.8 ± 9.96, 31.9 ± 7.01, 28 ± 6.11, and 20.7 ± 5.78 ng/g) at 0.5, 1, 2, and 4 h (P < 0.05), respectively. The amount of Fe in liver exposed magnetic field showed a similar trend. Histological studies revealed an enhanced particle aggregation in the targeted liver area. Under the external magnetic field, the biodistribution of DOX-loaded PGMNs was changed compared to absence of magnet field, and the PGMNs were capable of carrying drug for targeting therapeutic purposes.
聚乙二醇修饰的 GoldMag 纳米颗粒(PGMNs)通过透射电子显微镜、动态光散射、傅里叶变换红外光谱和振动样品磁强计等多种分析方法进行了合成和表征。这里,我们展示了复合纳米颗粒的饱和磁化强度为 34 emu/g,平均直径为 50 nm。动力学分析表明,PGMNs 的最大载药量为 107.78 mg/g。载有 DOX(载 DOX 的 PGMNs)的 PGMNs 在最初的 4 小时内表现出控制药物释放模式,然后在 4 天内缓慢持续释放。体内载 DOX 的 PGMNs 的生物分布表明,暴露于磁场组的 DOX 浓度(60.7 ± 8.14、53.6 ± 4.89、44.8 ± 6.41 和 38.4 ± 2.58 ng/g)明显高于未施加磁场组(40.8 ± 9.96、31.9 ± 7.01、28 ± 6.11 和 20.7 ± 5.78 ng/g),分别在 0.5、1、2 和 4 h(P < 0.05)。暴露于磁场的肝中铁含量也呈现出类似的趋势。组织学研究显示,在靶向肝区的颗粒聚集增强。在外部磁场下,与无磁场相比,载 DOX 的 PGMNs 的生物分布发生了变化,PGMNs 能够携带药物进行靶向治疗。